Cargando…
Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding. We studied the safety and clinical outcomes of switching from DAPT to aspirin monotherapy at 3 months after ZES implantation. We retrospectively evaluated 168 consecutive patients with coronary...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649238/ https://www.ncbi.nlm.nih.gov/pubmed/23762606 http://dx.doi.org/10.1155/2013/518968 |
_version_ | 1782268931077046272 |
---|---|
author | Wada, Tadashi Nakahama, Makoto Toda, Hironobu Watanabe, Atsuyuki Hashimoto, Katsushi Terasaka, Ritsuko Nakamura, Kazufumi Yamada, Nobuyuki Ito, Hiroshi |
author_facet | Wada, Tadashi Nakahama, Makoto Toda, Hironobu Watanabe, Atsuyuki Hashimoto, Katsushi Terasaka, Ritsuko Nakamura, Kazufumi Yamada, Nobuyuki Ito, Hiroshi |
author_sort | Wada, Tadashi |
collection | PubMed |
description | Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding. We studied the safety and clinical outcomes of switching from DAPT to aspirin monotherapy at 3 months after ZES implantation. We retrospectively evaluated 168 consecutive patients with coronary artery disease who had been implanted with a ZES from June 2009 through March 2010. After excluding 40 patients according to exclusion criteria such as myocardial infarction, 128 patients were divided into a 3-month DAPT group (67 patients, 88 lesions) and a 12-month conventional DAPT group (61 patients, 81 lesions). Coronary angiographic followup and clinical followup were conducted at more than 8 months and at 12 months after ZES implantation, respectively. Minor and major bleeding events, stent thrombosis (ST), and major adverse cardiac events (MACE) (death, myocardial infarction, cerebrovascular accident, target lesion revascularization, and target vessel revascularization) were evaluated. There were no statistically significant differences in the incidences of ST and MACE between the two groups. The incidence of bleeding events was significantly lower in the 3-month group than in the 12-month group (1.5% versus 11.5%, P < 0.05). DAPT can be safely discontinued at 3 months after ZES implantation, which reduces bleeding risk. |
format | Online Article Text |
id | pubmed-3649238 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-36492382013-06-12 Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease Wada, Tadashi Nakahama, Makoto Toda, Hironobu Watanabe, Atsuyuki Hashimoto, Katsushi Terasaka, Ritsuko Nakamura, Kazufumi Yamada, Nobuyuki Ito, Hiroshi ISRN Cardiol Clinical Study Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding. We studied the safety and clinical outcomes of switching from DAPT to aspirin monotherapy at 3 months after ZES implantation. We retrospectively evaluated 168 consecutive patients with coronary artery disease who had been implanted with a ZES from June 2009 through March 2010. After excluding 40 patients according to exclusion criteria such as myocardial infarction, 128 patients were divided into a 3-month DAPT group (67 patients, 88 lesions) and a 12-month conventional DAPT group (61 patients, 81 lesions). Coronary angiographic followup and clinical followup were conducted at more than 8 months and at 12 months after ZES implantation, respectively. Minor and major bleeding events, stent thrombosis (ST), and major adverse cardiac events (MACE) (death, myocardial infarction, cerebrovascular accident, target lesion revascularization, and target vessel revascularization) were evaluated. There were no statistically significant differences in the incidences of ST and MACE between the two groups. The incidence of bleeding events was significantly lower in the 3-month group than in the 12-month group (1.5% versus 11.5%, P < 0.05). DAPT can be safely discontinued at 3 months after ZES implantation, which reduces bleeding risk. Hindawi Publishing Corporation 2013-04-04 /pmc/articles/PMC3649238/ /pubmed/23762606 http://dx.doi.org/10.1155/2013/518968 Text en Copyright © 2013 Tadashi Wada et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Wada, Tadashi Nakahama, Makoto Toda, Hironobu Watanabe, Atsuyuki Hashimoto, Katsushi Terasaka, Ritsuko Nakamura, Kazufumi Yamada, Nobuyuki Ito, Hiroshi Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title | Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title_full | Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title_fullStr | Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title_full_unstemmed | Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title_short | Dual Antiplatelet Therapy Can Be Discontinued at Three Months after Implantation of Zotarolimus-Eluting Stent in Patients with Coronary Artery Disease |
title_sort | dual antiplatelet therapy can be discontinued at three months after implantation of zotarolimus-eluting stent in patients with coronary artery disease |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3649238/ https://www.ncbi.nlm.nih.gov/pubmed/23762606 http://dx.doi.org/10.1155/2013/518968 |
work_keys_str_mv | AT wadatadashi dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT nakahamamakoto dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT todahironobu dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT watanabeatsuyuki dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT hashimotokatsushi dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT terasakaritsuko dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT nakamurakazufumi dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT yamadanobuyuki dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease AT itohiroshi dualantiplatelettherapycanbediscontinuedatthreemonthsafterimplantationofzotarolimuselutingstentinpatientswithcoronaryarterydisease |